This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Abraham, Fruchter & Twersky, LLP Announces That A Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc.

Stocks in this article: SPPI

Fourth graph, first sentence of release should read: If you purchased the common stock of Spectrum from August 8, 2012 through March 12, 2013 (the “Class”) and you wish to serve as lead plaintiff in this action, you must move the Court no later than May 13, 2013. (sted May 16, 2013).

The corrected release reads:


Abraham, Fruchter & Twersky, LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of all persons or entities who purchased the common stock of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:SPPI) from August 8, 2012 through March 12, 2013, inclusive (the “Class Period”). The complaint alleges violations of Section 10(b) of the Securities and Exchange Act of 1934 and Rule 10b-5, promulgated thereunder, against the Company and certain of its officers and directors.

The complaint alleges that throughout the Class Period, defendants made false and misleading statements to the investing public by dismissing concerns that sales of FUSILEV ® (an oncology drug manufactured by Spectrum) would be adversely affected by increased supplies of leucovorin (a generic and competing drug of FUSILEV) and concealing the impact that the increased availability of leucovorin would have on FUSILEV sales. The complaint alleges that the defendants knew that when the availability of leucovorin increased, Spectrum would not be able to sustain its business outlook and revenue projections.

After the market closed on March 12, 2013, Spectrum surprised the market by reporting in a press release that sales of FUSILEV would be dropping significantly due to “a change in ordering patterns of FUSILEV.” The Company also decreased their full-year 2013 revenues forecast to a range of $160 to $180 million, significantly lower than analysts’ revenue expectations of $297.33 million. In a reaction to this news, shares of Spectrum common stock fell $4.64 per share, or 37%, on extremely high trading volume of 22.5 million shares.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs